Hollis-Eden on hold by Jefferies

Hollis-Eden Pharmaceuticals, Inc. was given a hold rating and a $5.50 price target by Jefferies & Co., Inc. analyst Adam Walsh. The company's first-quarter loss per share of $0.30 was in line with Street consensus. Shares of the San Diego, Calif., pharmaceutical company were up $0.05, or 1.05%, at $4.79 on volume of 97,114 shares versus the three-month running average of 156,716 shares. (Nasdaq: HEPH)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.